Exploring the Benefits of GMP for Early Phase Development Over USP Compounding
In the world of pharmaceutical research, the formulation and production methodologies can mean the difference between success and failure in early phase clinical trials. Upcoming on November 6, 2025, Xtalks will host a free webinar titled "Beyond the Bench: The Advantages of GMP over USP Compounding in Early Phase Development". This important session aims to illuminate the distinctions between Good Manufacturing Practice (GMP) and the United States Pharmacopeia (USP) compounding.
Participants will gain pivotal insights outlining the inherent advantages of GMP, particularly hinting at its role in boosting data integrity, reproducibility, and compliance with regulatory standards. Often, researchers lean towards USP due to its perceived speed and familiarity. However, the hidden risks associated with this choice can lead to inconsistencies and compromise the analytical depth crucial in clinical trials.
The session will feature experienced professionals from ICON, including Mindy Findlay, the Research Pharmacy Manager; Corey Ohnmacht, PhD, who oversees Bioanalytical and Quality Control Lab Services; and Jeffrey Hinchey, PharmD, Senior Research Pharmacy Manager. Together, they will highlight both theoretical insights and real-world case studies that exemplify where USP-based methodologies have fallen short in delivering critical analytical results. Conversely, they will explore how implementing GMP could have led to different outcomes.
Participants can expect to learn about the optimal designs for GMP facilities, emphasizing factors that underpin quality and efficiency. Discussion points will include cleanroom architecture, workflow segregation, established environmental monitoring systems, quality assurance integration, and collaboration across QC laboratories. Ensuring proper equipment calibration will also be a significant point of focus.
In this increasingly regulatory environment, the necessity for translational fidelity has never been more pronounced. The disparity between GMP and USP in methodology becomes not merely a technical choice but a strategic one with considerable implications for future research initiatives.
Moreover, as the demand for higher standards continues to escalate, the strategic implementation of GMP during early stage development is likely to lead not only to time savings but also to better resource management in the long run.
This is a crucial opportunity for anyone involved in pharmaceutical research, from pharmaceutical companies to academic institutions. By pivoting towards GMP, researchers are setting a solid foundation for their studies, ensuring that they are better equipped to meet the demanding expectations of regulatory bodies.
To register for the webinar, which takes place at 11am EST (5pm CET), please visit the Xtalks website. By participating in this event, attendees will not only grasp the nuances between GMP and USP but also arm themselves with knowledge that can be a game-changer in their pharmaceutical research endeavors.
Participants will gain pivotal insights outlining the inherent advantages of GMP, particularly hinting at its role in boosting data integrity, reproducibility, and compliance with regulatory standards. Often, researchers lean towards USP due to its perceived speed and familiarity. However, the hidden risks associated with this choice can lead to inconsistencies and compromise the analytical depth crucial in clinical trials.
The session will feature experienced professionals from ICON, including Mindy Findlay, the Research Pharmacy Manager; Corey Ohnmacht, PhD, who oversees Bioanalytical and Quality Control Lab Services; and Jeffrey Hinchey, PharmD, Senior Research Pharmacy Manager. Together, they will highlight both theoretical insights and real-world case studies that exemplify where USP-based methodologies have fallen short in delivering critical analytical results. Conversely, they will explore how implementing GMP could have led to different outcomes.
Participants can expect to learn about the optimal designs for GMP facilities, emphasizing factors that underpin quality and efficiency. Discussion points will include cleanroom architecture, workflow segregation, established environmental monitoring systems, quality assurance integration, and collaboration across QC laboratories. Ensuring proper equipment calibration will also be a significant point of focus.
In this increasingly regulatory environment, the necessity for translational fidelity has never been more pronounced. The disparity between GMP and USP in methodology becomes not merely a technical choice but a strategic one with considerable implications for future research initiatives.
Moreover, as the demand for higher standards continues to escalate, the strategic implementation of GMP during early stage development is likely to lead not only to time savings but also to better resource management in the long run.
This is a crucial opportunity for anyone involved in pharmaceutical research, from pharmaceutical companies to academic institutions. By pivoting towards GMP, researchers are setting a solid foundation for their studies, ensuring that they are better equipped to meet the demanding expectations of regulatory bodies.
To register for the webinar, which takes place at 11am EST (5pm CET), please visit the Xtalks website. By participating in this event, attendees will not only grasp the nuances between GMP and USP but also arm themselves with knowledge that can be a game-changer in their pharmaceutical research endeavors.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.